A human monoclonal antibody against glycoprotein gp III of varicella zoster virus (VZV) and a hybridoma which produces the same.

The invention also concerns the hybridoma filed under access number CNCM I-2282, and the monoclonal antibody produced by said hybridoma.

An anti-histone H1 monoclonal antibody that is useful for the inhibition, estimation or diagnosis of immunological rejection at organ transplant; a hybridoma capable of producing the same; and a relevant polypeptide.

A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced.

The invention concerns a hybridome called 5C5 (CNCM n° I-2184) and the monoclonal antibody 5C5 which it produces.

This monoclonal antibody is designated WM-65 and the hybridoma cell line is designated F56-1D5 (ECACC).

To select a hybridoma of the desired kind in any case means a huge amount of effort and, above all, it is not certain that this hybridoma can be selected at all.

Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Also described is a hybridoma capable of producing monoclonal antibodies which bind specifically to the protein of the invention.

A monoclonal antibody that recognises glucose transporter 2 (GLUT2) is described, as well as a hybridoma that produces the antibody.

Hybridoma secreting the antibodies are disclosed, as well as diagnostic methods using the antibodies.

So, who is the winner in “Native vs Hybrid” battle?

Before that he served as the Head of Histopathology and Hybridoma Unit at QBI.

So, who is the winner in "Native vs Hybrid" battle?

The invention provides an anti-idiotypic monoclonal antibody produced by hybridoma designated 82H11B9F, having ATCC Accession No. HB 11548.